ORGANIZATION OF INTEGRATIVE CARE FOR PATIENTS WITH ONCOPATHOLOGY

Clinical testing (providing of integrative care) was conducted to determine the methodology for the treatment and rehabilitation of patients who were previously denied in other hospitals. Defined the methodological approaches to the choice of the treatment, causing minimal harm to patients in other health care organizations were offered only symptomatic or palliative therapy.

The purpose of the study:

– improvement the quality of life;

– increasing the terms of survival;

– reduction of depressive state with confirmation of the diagnosis;

– reducing the negative effects of the treatment.

Patients and methods. In clinical trials 47 patients with stage IV of disease were involved, including in the integrative treatment group was 25 patients (16 women and 9 men), the group standard of treatment, 22 patients (15 women and 7 men). The group consisted of the patients with recurrences of the tumours, and patients after primary treatment at a late stage of the disease. The combination of all possible types of treatment (standard methods of treatment, immune therapy with drug “Helixor®  M”, psychological assistance) was performed depending on the disease defined by the overall clinical picture and psychological readiness of patients to one or another form of therapy. The choice of the injection scheme in order to quickly transition to a maximally tolerated doses was carried out using the control functional state.

Results. The use of this method in comparison with the control group showed improvement in the quality of life of patients and increase in terms of survival.

Conclusion. The results that are obtained during clinical testing confirmed the positive effect of integrative treatment of patients with oncologic pathology when choosing the best course and combination of treatments, depending on the needs and course of the disease. Also the immunotherapy with drug “Helixor®  M” showed efficacy in the treatment of viral infections for patients with tumors and without them.

1. Parin V. V., Baevskii R. M. Vvedenie v meditsinskuyu kibernetiku [Introduction to medical Cybernetics]. Moscow: “Meditsina” Publ., 1966, 220 p. (In Russian).

2. Аnokhin P. K. Kibernetika funktsional’nykh sistem. Izbrannye Trudy [Cybernetics of functional systems]. Ed by Sudakov K. V. Moscow: “Meditsina” Publ., 1998, 400 p. (In Russian).

3. Fleishman A. N. Medlennye kolebaniya gemodinamiki. Teoriya, prakticheskoe primenenie v klinicheskoi meditsine i profilaktike [The slow oscillations of hemodynamics. Theory, practical application in clinical medicine and prevention]. Novosibirsk, 1998, 264 p. (In Russian).

4. Fleishman A. N. Variabel’nost’ ritma serdtsa i medlennye kolebaniya gemodinamiki: nelineinye fenomeny v klinicheskoi praktike [The heart rate variability and slow oscillations hemodynamics: nonlinear phenomena in clinical practice]. 2nd ed. 2009, 194 p. (In Russian).

5. Orlov Yu. M. Ozdoravlivayushchee myshlenie [Healthy thinking]. Мoscow: “Slaiding” Publ., 2006, 96 p (In Russian).

6. Baevskii R. M., Bersen’eva A. P. Otsenka adaptivnykh vozmozhnostei organizma i riska razvitiya zabolevanii [Evaluation of adaptive opportunities of an organism and risk of diseases]. Мoscow: “Meditsina” Publ., 1997, 265 p. (In Russian).

7. Mechnikov I. Edutes sur la nature humaine: essai de philosophie optimiste. Paris: Masson. 1903, 399 p.

8. Büssing A. Mistletoe. The Genus Viscum. Harwood Academie Publishers, Singapore, 2000.

9. Steiner R. Geisteswissenschaft und Medizin. Dornach, Switzerland, 1985.

10. Kienle G. S., Berrino F., Büssing A., Portalupi E., Rosenzweig S., Kiene H. Mistletoe in cancer-a systematic review in controlled clinical trials. Eur J Med Res. 2003; 8 (3): 109–119.

11. Büssing A. In: Mistletoe. The Genus Viscum. Büssing A, editor. Amsterdam: Harwood Academic Publishers; 2000. Biological and pharmacological properties of Viscum album L; pp. 123–182.

12. Büssing A. In: Mistletoe. The Genus Viscum. Büssing A, editor. Amsterdam: Harwood Academic Publishers; 2000. History of mistletoe uses; pp. 1–6.

13. Lavalle E. C., Grant G., Puszai A., Pfuller U., Leavy O., Mcneela E., et al. Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology. 2002; 107 (2): 268–274. DOI: http://dx.doi.org/10.1046/j.1365–2567.2002.01492.x

14. Nozdrachev A. D., Mar’yanovich A. T., Polyakov E. L., Sibarov A. D., Khavinson V. Kh. Nobelevskie premii po fiziologii ili meditsine za 100 let [Nobel prize in physiology or medicine for 100 years]. Saint Petersburg: “Gumanistika” Publ., 2002, 688 p. (In Russian).

15. Piano B. K., Wang Y. X., Xie G. R., Mansmann U., Matthes H., Beuth J., et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res. 2004 Jan-Feb; 24 (1): 303–309. DOI: http://ar.iiarjournals.org/content/24/1/303.long

16. Mansky P. J., Wallerstedt D. B., Sannes T. S., Stagl J., Johnson L. L., Blackman M. R., et al. NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med. 2013; 2013: 964592. DOI: http://dx.doi.org/10.1155/2013/964592

17. Schad F., et al. Safety report for Helixorâ from the Network Oncology Clinical Database. Forschungsinstitut Havelhoehe, Berlin, 2013.

18. Sandeep Roy. Breast Tumor Regression using Mistletoe Extract: An evidence from an Indian Clinic. Helix. 2015; 2: 651–655.

19. Beuth J. Grundlagen der Komplemetärokonkologie. Theorie und Praxis, Hippokrates Velag, Stuttgart 2002.

20. Ostermann T., Bussing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: ameta-analysis. Explore. 2012; 8 (5): 277–281. DOI: http://dx.doi.org/10.1016/j.explore.2012.06.005

21. Hajto T., Fodor K., Perjesi P., Nemeth P. Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evid Based Complement Alternat Med. 2011; 2011: 298972. DOI: http://dx.doi.org/10.1093/ecam/nep191

22. Ostermann T., Raak C., Bussing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC cancer. 2009; 9: 451. DOI: http://dx.doi.org/10.1186/1471–2407–9-451

23. Thies A., Dantel P., Meyer A., Pfüller U., Schumacher U. Low-dose mistletoe lectin-1 reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer. 2008; 98 (1): 106–112. DOI: http://dx.doi.org/10.1038/sj.bjc.6604106